FXEMPIRE
All
Ad
Corona Virus
Stay Safe, FollowGuidance
World
99,396,765Confirmed
2,131,897Deaths
71,466,891Recovered
Fetching Location Data…
Advertisement
Advertisement
Bob Mason
Corona

The Latest

It’s a big day on the COVID-19 vaccine front, with the FDA scheduled to review BioNTech/Pfizer Inc.’s mRNA vaccine later today.

Lagging behind the UK approval that came last week, there will be plenty of pressure on the FDA to give the approval.

COVID-19 cases across the U.S continues to rise as U.S states make their way through the winter months.

Approval would mean that BioNTech/Pfizer Inc. will be able to begin distributing vaccines as early as the weekend.

Unfortunately, supply chain issues have meant that vaccine production for the year will be as much as 50% lower than initially forecasted.

This means that the continued rise in new COVID-19 cases across the U.S is unlikely to abate anytime soon.

Advertisement

What’s next?

Assuming that the FDA approves BioNTech/Pfizer Inc.’s EUA, the U.S government is due to receive 25 million doses by the end of the year.

That just covers 12.5 million of more than 330 million people living in the U.S.

When considering the CDC’s high priority vaccine recipients, the number of vaccines is not enough to cover the first priority group.

This will leave doctors, nurses, lab technicians, and EMT and hospital staff at risk, not to mention the most vulnerable.

With prioritization ultimately sitting at the state level rather than the Federal level this will leave the most adversely affected states vulnerable to further spikes.

Based on the sheer numbers, Moderna Inc. and AstraZeneca will need to also be in a position to ease demand pressures.

The CDC’s phase sequence leaves adults with high-risk medical conditions and the over 65s in phase 1c.

In phase 1a are healthcare personnel and LTCF residents, with phase 1b including essential workers.

To put it into perspective, the CDC also provided estimate numbers of vaccine recipients within the phase 1a category:

  • Healthcare personnel – Approx. 21million.
  • Long-term Care Facility Residents (LTCF) – Approx. 3 million.

A total of 25 million BioNTech/Pfizer Inc. doses are not enough to cover healthcare personnel, let alone LTCF and phase 1b and phase 1c recipients.

With Moderna Inc. and AstraZeneca also delivering vaccines, the reality is that a single dose vaccine is needed.

The Latest COVID-19 Numbers

At the time of writing, the total number of confirmed COVID-19 cases stood at 69,381,422. Conditions in the U.S and parts of Europe have continued to deteriorate. The total number of U.S cases has risen to 15,824,444.

India and Brazil have reported a total of 9,767,371 and 6,673,118 cases respectively, sitting behind the U.S as the worst affected.

France (2,324,216), Italy (1,770,149), Spain (1,725,473), and Germany (1,245,729) are also in desperate need of a vaccine. For the EU, however, vaccine reviews are not due until next month.

Other Pharmas

While BioNTech/Pfizer Inc. and Moderna Inc. are leading the race, there is a desperate need for more vaccines.

In reality, there is not only the need for more vaccines but single-dose vaccines.

This week, Johnson & Johnson announced that results from clinical trials will be released earlier than previously expected.

More good news is going to be needed for there to be a credible threat to the COVID-19 pandemic.

Trust issues mean that vaccines from countries such as China and Russia would unlikely be considered for review.

This leaves the door ajar for the rest of the major pharmas to deliver. These include but are not limited to the following:

U.S Headquartered

Mateon Therapeutics: Listed on OTCMKTS (“MATN”) and headquartered in California.

Merck & Co.: Listed on the New York Stock Exchange (“MRK”) and headquartered in New Jersey, USA.

Moderna Inc.: Listed on the NASDAQ (“MRNA”) and headquartered in Cambridge, Massachusetts, USA.

Pfizer Inc.: Listed on the New York Stock Exchange (“PFE”) and headquartered in New York City. (Pfizer Inc. has partnered with Germany’s BioNTech SE)

Sorrento Therapeutics: Listed on the NASDAQ (“SRNE”) and headquartered in California. Currently trailing many of the front runners in the race for an effective vaccine.

Talem Therapeutics: This is a wholly-owned subsidiary of ImmunoPrecise Antibodies USA. Its parent company, ImmunoPrecise Antibodies Ltd is listed on the Toronto Stock Exchange.

Tonix Pharmaceuticals: Listed on the NASDAQ (“TNXP”) and headquartered in New Jersey.

Europe Headquartered

AstraZeneca: Listed on the London Stock Exchange (“AZN”) and headquartered in Cambridge, England and Sodertalje, Sweden.

GlaxoSmithKline: Listed on the London Stock Exchange (“GSK”) and headquartered in Brentford, England.

Grifols, S.A: Listed on the Bolsa de Madrid (“GRF”) and headquartered in Barcelona, Spain.

Asia Headquartered:

GC Pharma: Listed on the Korea Stock Exchange (“006280”) and headquartered in Yongin, South Korea.

The Global Financial Markets

Progress by the leading pharmas continues to support riskier assets. Hopes of other pharmas completing successful trials have also provided support.

Clinical trial results, however, will need to deliver impressive numbers for a global end to the COVID-19 pandemic.

Failure for other pharmas to begin rolling out vaccines will test support for riskier assets.

The sheer numbers needing vaccines on the front line mean that other high priority recipients remain exposed. Therefore, a credible threat remains to the likes of the EU and beyond that have fallen behind Britain, and possibly the U.S, on approving effective vaccines for circulation.

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker

  • Your capital is at risk
IMPORTANT DISCLAIMERS
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
RISK DISCLAIMER
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.
FOLLOW US